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http://dx.doi.org/10.1016/j.ccr.2013.01.015SUMMARYNotch1 is a rational therapeutic target in several human cancers, but as a transcriptional regulator, it poses
a drug discovery challenge. To identify Notch1 modulators, we performed two cell-based, high-throughput
screens for small-molecule inhibitors and cDNA enhancers of a NOTCH1 allele bearing a leukemia-
associated mutation. Sarco/endoplasmic reticulum calcium ATPase (SERCA) channels emerged at the
intersection of these complementary screens. SERCA inhibition preferentially impairs the maturation and
activity of mutated Notch1 receptors and induces a G0/G1 arrest in NOTCH1-mutated human leukemia cells.
A small-molecule SERCA inhibitor has on-target activity in two mouse models of human leukemia and
interferes with Notch signaling in Drosophila. These studies ‘‘credential’’ SERCA as a therapeutic target in
cancers associated with NOTCH1 mutations.INTRODUCTION
Selective expression of transcription factors directs the hierar-
chical specification of the hematopoietic lineage, and acquired
mutations that perturb the function of these factors have a central
role in leukemia pathogenesis. A prime example involves
Notch1, a surface receptor that is essential for T-cell progenitor
specification and maturation. Acquired mutations that activateSignificance
Notch1 is aberrant in many malignancies, with both gain and lo
therapies selectively targetingmutant Notch1 receptors. T cell a
need of better treatment approaches, is one disease notable fo
identify SERCA inhibition as an approach to selectively impa
demonstrate the antileukemia activity of this strategy both in vit
in hereditary diseases and cancer, our study also suggests that
to altered Notch signaling.
390 Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc.Notch1 are found in 40% to 70% of childhood and adult T-cell
acute lymphoblastic leukemia (T-ALL) (Lee et al., 2005; Mansour
et al., 2006; Weng et al., 2004). Moreover, recent reports identi-
fied NOTCH1 activating mutations in 10%–15% of chronic
lymphocytic leukemia (CLL) (Di Ianni et al., 2009; Puente et al.,
2011) and mantle cell lymphoma (Kridel et al., 2012).
Notch receptors regulate many aspects of normal develop-
ment and tissue homeostasis (reviewed in Kopan and Ilagan,ss-of-function mutations reported, highlighting the need for
cute lymphoblastic leukemia (T-ALL), a high-risk leukemia in
r frequent, activating mutations inNOTCH1. In this study, we
ir the maturation of mutant Notch1 receptors in T-ALL and
ro and in vivo.With increasing evidence of SERCAmutations
aberrant SERCA activity might contribute to diseases linked
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ration by a furin-like protease, leading to the formation of two,
noncovalently associated subunits. Signaling is normally initi-
ated by binding of the Notch ectodomain to a ligand of the
DSL family expressed on a neighboring cell. This interaction trig-
gers two additional, successive proteolytic cleavages in the
Notch transmembrane subunit. The first, mediated by ADAM-
10 or ADAM-17 (Brou et al., 2000), occurs within a juxtamem-
brane negative regulatory region (NRR) at a site that is protected
in the Notch off state (Gordon et al., 2009; Gordon et al., 2007).
This cleavage within the Notch transmembrane domain creates
a short-lived intermediate that is primed for secondary cleavage
by the g-secretase complex, an event that liberates the intracel-
lular domain of Notch1 (ICN). ICN translocates to the nucleus,
associates with the DNA-binding factor RBPJ, and recruits co-
activators of the Mastermind-like (MAML) family to activate
expression of target genes.
Each of the proteolytic steps involved in the activation
of Notch receptors is a potential therapeutic target. Indeed,
g-secretase inhibitors (GSIs) have anti-T-ALL activity in vitro
(Weng et al., 2004) and in vivo (Cullion et al., 2009; Real et al.,
2009). The GSI MK-0752 was tested in a phase I clinical trial in
patients with relapsed acute leukemia (DeAngelo et al., 2006).
This trial was halted, however, due to gastrointestinal toxicity
thought to be related to chronic pan-Notch receptor inhibition in
gut progenitor cells (Wong et al., 2004). Thus, other approaches
to Notch1 inhibition are desirable.
Historically, it has been difficult to develop high-throughput
assays for small molecules that disrupt protein-DNA or
protein-protein interactions (Darnell, 2002). Recently, there has
been renewed interest in cell-based screening to address the
problem of ‘‘undruggable’’ targets using various approaches
(Carpenter, 2007; Inglese et al., 2007; Stegmaier et al., 2004).
Gene expression-based high-throughput screening (GE-HTS)
is a chemical genomic approach in which gene expression
signatures serve as surrogates for cellular states (Hahn et al.,
2008; Stegmaier et al., 2004). One application of GE-HTS is for
the identification of small molecules that modulate transcrip-
tional signatures produced by aberrantly activated transcription
factors (Corsello et al., 2009). A limitation of cell-based assays is
that identifying the biologically relevant target of the small mole-
cule can be a daunting task. One way to overcome this chal-
lenge is to design multiple, integrated cell-based screens and
then to focus on common emerging hits. With the availability
of genome-scale cDNA collections, overexpression screens
have also proven to be powerful tools to probe biological path-
ways and to identify the protein targets of small molecules. Here,
we used complementary GE-HTS and cDNA overexpression
screens to search for small-molecule modulators of Notch1
signaling in T-ALL.
RESULTS
Development of a GE-HTS Assay for Notch1 Inhibitors
Figure 1A outlines our approach. We first defined a robust
Notch1 transcriptional signature for the GE-HTS assay. We
selected a set of genes that defined the Notch1 activation state
from genomewide expression profiling of seven NOTCH1-
mutated T-ALL cell lines treated with the GSI compound E(Cpd E) (Palomero et al., 2006b). From a set of approximately
500 genes with differences of p < 0.01 by two-sided Student’s
t test, 28 genes with mean fold changes > 1.5 between the
Notch1 on versus off states (Figure 1B) and four invariant
control genes were selected and validated (Figure S1A avail-
able online). To confirm that the signature reports on Notch1
inhibition and not GSI treatment per se, we transduced
DND41 cells with Notch1-specific shRNA and demonstrated
induction of the Notch1 off signature (Figures S1B–S1D). This
is consistent with prior work in which we showed that GE-
HTS identified a Notch1 off signature in T-ALL cells treated
with a Notch1-specific inhibitory antibody (Aste-Ame´zaga
et al., 2010). To ensure that the signature does not identify
generic growth inhibitors or cellular toxins, we treated DND41
cells with drugs known to be active against T-ALL cells. These
drugs inhibited growth but did not induce the Notch1 off signa-
ture (Figures S1E–S1F).
Identification of Small Molecules that Modulate Notch1
We screened 3,801 drugs or drug-like compounds in the human
T-ALL cell line DND41. GE-HTS data were collected after 72 hr of
treatment as previously described (Peck et al., 2006). Because
true-positives are more likely to score by multiple scoring
metrics, we applied a consensus classification system requiring
hits to score in multiple algorithms: summed score, weighted
summed score, K-nearest neighbor, naive Bayes classification,
and support vector machine (Figure 1C; Figure S1G) (Banerji
et al., 2012). A total of 16 compounds (Table S1) selected for vali-
dation based on these criteria were retested in a 2-fold dose-
response series in DND41, MOLT4, and PF382 cell lines.
Notably, multiple compounds reported to modulate calcium
ion flux scored as dose-dependent Notch pathway inhibitors in
all of the cell lines tested (Figures S1H–S1J).
A cDNA Library Screen Identifies SERCA as a Notch
Signaling Enhancer
A complementary cDNA library screen for factors that enhance
the signaling activity of the Notch1 mutant L1601PDP
was simultaneously conducted in the osteosarcoma cell line
U2OS. L1601PDP contains the same heterodimerization muta-
tion that is present in the MOLT4 and KOPTK1 cell lines in cis
with a PEST domain deletion (Chiang et al., 2008), a com-
bination that is found in approximately 10%–15% of human
T-ALL (Weng et al., 2004). U2OS cells were selected for the
screen because they are readily transfected and have very
low basal Notch signaling tone, a feature that produces favor-
able signal-to-noise ratios. A total of 18,000 open reading
frames were scored for their ability to enhance L1601PDP-
dependent activation of a Notch luciferase reporter. Among the
top hits were ATP2A1, ATP2A2, and ATP2A3 (Figure 1D), which
encode SERCA1, SERCA2, and SERCA3, respectively. Sarco/
endoplasmic reticulum calcium ATPases (SERCAs) are closely
related, inwardly directed, ATP-dependent calcium pumps that
localize to the endoplasmic reticulum (ER). Retesting confirmed
that ATP2A2 and ATP2A3 potentiate L1601PDP-dependent
signaling (Figure 1E). Of note, loss-of-function mutations in
a Drosophila SERCA homolog, Ca-P60A, have been reported to
produce Notch loss-of-function phenotypes in this model
organism by altering Notch trafficking (Periz and Fortini, 1999).Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc. 391
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Figure 1. Identification of SERCA at the Intersection of Two High-Throughput Screens
(A) Notch1 inhibitory modulators were identified using GE-HTS in DND41 cells, and these results were integrated with results from a cDNA library screen for
factors enhancing the signaling activity of the leukemogenic NOTCH1 allele, L1601PDP. ORF, open reading frame; LMA, ligation-mediated amplification.
(legend continued on next page)
Cancer Cell
SERCA Is a Target in NOTCH1 Mutated Cancer
392 Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc.
Cancer Cell
SERCA Is a Target in NOTCH1 Mutated CancerThus, calcium modulators emerged at the nexus of two comple-
mentary screens.
Thapsigargin Targets the Notch Pathway
One of the small molecules that scored in our GE-HTS screen
across four scoring metrics was thapsigargicin, an analog of
thapsigargin, a highly potent natural product inhibitor of SERCA.
Low nanomolar concentrations of thapsigargin induced the
Notch1 off signature in a dose-dependent fashion in NOTCH1
mutant T-ALL cells (Figure 2A) and reduced the expression of
the direct Notch1 target genes MYC, HES1, and DTX1 (Fig-
ure 2B). Subnanomolar concentrations of thapsigargin also
inhibited the expression of a Notch reporter by L1601PDP in
U2OS cells (Figure 2C).
Notch1 inhibition results in G0/G1 arrest in human T-ALL cells
(Weng et al., 2004) and decreased T-ALL cell size (Palomero
et al., 2006b; Weng et al., 2006). As expected, thapsigargin also
induced aG0/G1 arrest (Figure 3A) anda decrease in cell size (Fig-
ure 3B) inNOTCH1-mutated T-ALL cell lines.We next studied the
effect of thapsigargin in a panel of T-ALL cell lines that contain
activating mutations in the heterodimerization domain (HD) of
Notch1 and/or deletions in the degradation domain (PEST). Three
T-ALL cell lines reported to be highly sensitive to GSI (ALL/SIL,
DND41, and KOPTK1) were more sensitive to thapsigargin as
measured by inhibition of cell growth and induction of apoptosis
compared to two cell lines with intermediate sensitivity to GSI
(MOLT4 and PF382) (Figure 3C). Furthermore, 24 hr of thapsigar-
gin treatment decreased ICN1 levels in T-ALL cells (Figure 4A). As
a further test of the idea that thapsigargin acts by preventing
Notch1 activation, the Notch1-dependent T-ALL cell lines
MOLT4andDND41were transducedwith anemptyMigR1vector
or with MigR1-ICN1 (Figure 4B). Transduction of ICN1, which lies
downstream of the g-secretase cleavage step in Notch activa-
tion, prevented induction of the Notch1 off signature (Figure 4C),
growth inhibition (Figure 4D), G0/G1 cell cycle arrest (Figure 4E),
and induction of apoptosis (Figure 4F) by thapsigargin. In
contrast, empty MigR1 had no effect on these readouts of Notch
inhibition. These results are consistent with a Notch pathway
inhibitory effect of thapsigargin at low nanomolar concentrations.
Thapsigargin Interferes with Notch1 Maturation
Multiple compounds scoring in our screen, including thapsigar-
gin, are predicted to alter intracellular calcium. For example,
thapsigargin and cyclopiazonic acid are known Ca2+ATPase
inhibitors, impairing calcium entry into the ER. Of note, multiple
EGF repeats and all three Lin12/Notch repeats in the extracel-(B) Notch1 off signature genes derived from the expression profiling of T-ALL cel
duplicate with Cpd E (0.5 mM) or vehicle for 24 hr. The rows represent the 28 gene
and dark blue indicates low gene expression by Affymetrix microarray profiling.
(C) The x axis indicates the number ofmethods (summed score, weighted summed
y axis the fraction of chemicals that scored for the number of methods. SERCA
number of methods is noted above each column.
(D) Notch1 gain-of-function primary screen data for the negative (empty vector) a
the fold induction of luciferase signal for each replicate normalized to the popula
(E) Retesting of cDNAs scoring in the Notch-sensitive luciferase reporter. Lucifer
Errors bars denote the mean ± SD of 10 replicates. Statistical significance relativ
determined by Student’s t test.
See also Figure S1 and Table S1.lular domains of Notch receptors require calcium ions for proper
folding (Aster et al., 1999; Gordon et al., 2007; Hambleton et al.,
2004; Rand et al., 1997). We thus hypothesized that thapsigar-
gin, by altering ER Ca2+ concentrations, would inhibit Notch1
maturation in T-ALL cells.
To test this hypothesis, we first determined if thapsigargin
affected furin processing of Notch1, an event that occurs in the
late Golgi compartment. Lysates from T-ALL cell lines treated
with thapsigargin were immunoblotted with an antibody specific
for thecytoplasmicportionofNotch1 that recognizesbothunpro-
cessed Notch1 (270 kDa) and the furin-processed transmem-
brane subunit (110 kDa). Thapsigargin reduced the levels of
the furin-processed transmembrane Notch1 subunit, but not
the unprocessed full-length Notch1 precursor, in multiple T-ALL
cell lines (Figure 5A). Similar results were observed with the less
potent SERCA inhibitor cyclopiazonic acid (Figure S2).Misfolded
Notch1 receptors are expected to be retained in the ER/Golgi
compartment. Immunostaining revealed that thapsigargin treat-
ment reduced the levels of Notch1 on the cell surface (Figures
5B and 5C) and resulted in the colocalization of Notch1 and
giantin, aGolgimembrane protein (Figure 5D). Thus, thapsigargin
leads to defective Notch1 maturation in cultured T-ALL cells.
SERCA Antagonism Inhibits Notch Function and T-ALL
Growth In Vivo
To confirm that chemical and genetic inhibition of SERCA lead to
Notch inactivation in vivo, we evaluated a Drosophila intestinal
stem cell model in which Notch inhibition perturbs differentiation.
The adult midgut is maintained by pluripotent stem cells that give
rise to two populations of terminally differentiated daughter cells:
a large class of polyploid enterocyes (EC) and a smaller class of
diploid enteroendocrine (ee) cells (Micchelli and Perrimon, 2006;
Ohlstein and Spradling, 2007). The stem cells express escargot
(esg), a transcription factor, and Delta, a membrane-bound
ligand of the Notch receptor. High levels of Notch activation
are required for daughter cells to adopt the EC cell fate, whereas
lower levels of Notch activation specify daughters to adopt the
ee fate. Thus, when Notch is completely inhibited, daughter cells
fail to differentiate and remain as stem cells. By contrast, when
Notch signaling is partially inhibited, daughter cells fail to differ-
entiate into ECs and remain as stem cells or differentiate into ee
cells.
To enhance the sensitivity of fly-based drug assays, we used
transgenic flies that express a human RAF gain-of-function
cDNA, RAF(gof), in their intestinal stem cells. Expression of the
RAF(gof) cDNA results in rapid expansion of the esg+ population,l lines treated with Cpd E. The columns represent individual cell lines treated in
s selected for the Notch off signature. Dark red indicates high gene expression,
score, naive Bayes, K-nearest neighbor, and support vector machine), and the
inhibitors are indicated. The number of compounds scoring by the indicated
nd positive (MAML) controls versus SERCA-encoding cDNAs hits. Depicted is
tion median of reporter readout values of pcDNA3-L1601PDP (n = 184).
ase activity is expressed as relative activity compared to the pcDNA3 control.
e to pcDNA3 (*p < 0.05) and to pcDNA3-L1601PDP (#p < 0.05; ##p < 0.01) was
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Figure 2. Validation of SERCA as a Notch1
Modulator
(A) Induction of the Notch1 off score (weighted
summed score) measured by GE-HTS in DND41
(left) and MOLT4 (right) cells treated with thapsi-
gargin in 2-fold dilution for 72 hr. Error bars denote
the mean ± SD of 12 replicates for vehicle-treated
(DMSO 0.06%) cells and six replicates for thapsi-
gargin-treated cells.
(B) Expression of indicated Notch1 target genes in
DND41 treated in 2-fold dliution for 24 hr was
determined by quantitative RT-PCR. Error bars
indicate the mean ± SD of three replicates. Data
were analyzed using the DDCT method and
plotted as a percentage relative to the control gene
RPL13A.
(C) Effects of thapsigargin on the activation of
a Notch1 luciferase reporter by L1601PDP in
U2OS cells. Normalized luciferase activity relative
to a Renilla control was expressed as a percentage
of vehicle treatment. Error bars denote mean ± SD
of four replicates. Statistical significance (*p <
0.05; **p < 0.01; ***p < 0.001) in all panels was
determined by one-way analysis of variance
(ANOVA) using Bonferroni’s correction for multiple
comparison testing.
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SERCA Is a Target in NOTCH1 Mutated Cancerwhich is composed of not only diploid stem cells but also poly-
ploid EC daughter cells. When Notch is inhibited by feeding flies
either DAPT or Cpd E, both GSIs, stem cell daughters fail to
differentiate into EC cells and instead give rise mostly to addi-
tional stem cells, as well as some ee daughters (Figure 6A).
Cyclopiazonic acid and thapsigargin treatment also expanded
the stem cell and ee cell populations, thus phenocopying the
effects of GSI (Figure 6B).
If thapsigargin inhibits Notch signaling through effects on
calcium channels, then genetic modulation of SERCA should
produce similar phenotypes. Indeed, knockdown of Ca-P60A,
the only SERCA expressed in Drosophila, produced effects on
stem cell and ee cell pools similar to those induced by GSI,
thapsigargin, or cyclopiazonic acid treatment (Figure 6C).394 Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc.Thus, the results of chemical and genetic
studies are consistent with a model in
which SERCA inhibition by thapsigargin
impairs Notch signaling in vivo.
We next tested thapsigargin in a human
T-ALL xenograft model. Systemic admin-
istration of thapsigargin to SCID-beige
mice bearing MOLT-4 tumors inhibited
tumor growth compared to vehicle-
treated controls (Figure 6D). In addition,
ICN1 protein levels were diminished in
the thapsigargin-treated tumors com-
pared to vehicle-treated tumors (Figures
6E and S3A), linking growth inhibition to
Notch inhibition.
To demonstrate further that thapsigar-
gin impairs leukemic progression via
Notch signaling inhibition, we estab-lished a second T-ALL xenograft model in which DND41 cells
were transduced with MigR1 or MigR1-ICN1 and subsequently
propagated in NSG mice. Thapsigargin treatment markedly
decreased the growth of control tumors but had little effect on
tumors expressing ICN1 (Figures 6F and 6G), indicating that
tumor growth suppression by thapsigargin is mediated by inhibi-
tion of Notch1 signaling in the leukemic cells.
Prior studies demonstrated that gastrointestinal toxicity
and lack of sustained response were the major limitations of
first-generationGSIs (DeAngelo et al., 2006). It was hypothesized
that gastrointestinal toxicity was due to blockade of wild-type
Notch1 and Notch2 in the gut leading to intestinal secretory
metaplasia, increased number of goblet cells, and arrested prolif-
eration in the crypts of the small intestine (Milano et al., 2004;
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Figure 3. Thapsigargin Demonstrates Anti-Notch1 and Antileukemia Properties in T-ALL In Vitro
(A) Effect of thapsigargin treatment (6 days) on cell cycle of T-ALL cell lines, as assessed by measurement of DNA content on the viable fraction of cells.
(B) Effect of thapsigargin treatment for 24 hr on cell size as measured by forward-scatter flow cytometry.
(C) Effect of thapsigargin treatment on cell growth (left) and induction of apoptosis (right). Error bars denote mean ± SD of four replicates. Annexin V/PI staining of
T-ALL cells following 72 hr of treatment with 10 nM thapsigargin.
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Figure 4. Thapsigargin Demonstrates Notch1 On-Target Activity In Vitro
(A) Effect of 24 hr of thapsigargin treatment on the ICN1 level in T-ALL cells. The immunoblot was stained with anti-ICN1 antibody.
(B) ICN1 level in MigR1- or MigR1-ICN1-transduced cells. ICN1 is detected using an anti-ICN1 antibody.
(C) Theweighted summed score fold induction is shown for the Notch1 off signature after treatment of cells with thapsigargin or Cpd E for 48 hr. Error bars indicate
themean ± SDof 12 replicates for vehicle-treated and six replicates for GSI- or thapsigargin-treated cells. Statistical significance (***p < 0.001) was determined by
one-way ANOVA using Bonferroni’s correction for multiple comparison testing.
(D) Effect of thapsigargin on the growth of MigR1- or MigR1-ICN1-transduced DND41 cells. Normalized data are plotted relative to time 0. Error bars indicate
mean ± SD of four replicates. Statistical significance (***p < 0.001) was determined by two-way ANOVA with Bonferroni’s correction for multiple comparison
testing.
(E) Effect of 3 days of thapsigargin treatment on DNA content of MigR1- or MigR1-ICN1-transducedMOLT4 cells. Error bars indicate mean ± SD of two replicates
with results expressed relative to vehicle treatment. Statistical significance was determined by Student’s t test (**p < 0.01).
(F) Effect of 3 days of thapsigargin treatment on apoptosis of MigR1- or MigR1-ICN1-transduced DND41 cells. Error bars indicate mean ± SD of two replicates
with results expressed relative to vehicle. Statistical significance was determined by Student’s t test (**p < 0.01).
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gastrointestinal toxicity (Figures S3B and S3C), suggesting that
HD-mutated Notch1 receptors weremore sensitive to the effects396 Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc.of thapsigargin than wild-type Notch1/Notch2 receptors ex-
pressed in normal cells. These preclinical studies support
SERCA as a possible therapeutic target in T-ALL.
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Figure 5. Thapsigargin Impairs Notch1 Maturation in T-ALL Cell Lines
(A) Effect of thapsigargin treatment (24 hr) on Notch1 processing in T-ALL cell lines all with HD mutations, DND41 and ALL/SIL (L1594PDPEST), KOPTK1 and
MOLT4 (L1601PDPEST), and PF382 (L1575PDPEST). The blot was stained with an antibody against the C terminus of Notch1 that recognizes both the furin-
processed Notch1 transmembrane subunit (TM) and the unprocessed Notch1 precursor (FL).
(B and C) Effect of thapsigargin treatment (24 hr) on Notch1 cell surface staining, as assessed by flow cytometry (B) and staining of nonpermeabilized cells (C).
Scale bar, 10 mm.
(D) Effect of thapsigargin treatment (24 hr) on the subcellular localization of Notch1. Double-immunofluorescence staining of permeabilized DND41 cells stained
with anti-Notch1 (green) and Giantin (red) is shown. Colocalization is indicated by yellow signal. Scale bar, 10 mm.
See also Figure S2.
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Figure 6. SERCA Inhibition Causes Notch Loss-of-Function In Vivo
(A–C) Immunofluorescence staining of Drosophila midguts expressing GFP (green) and stained with anti-Delta (membrane red), antiprospero (nuclear red), and
DAPI (blue) is depicted. Treatment was with DAPT (400 mM) or Cpd E (100 mM) for 7 days in (A) and with cyclopiazonic acid (1 mM) or thapsigargin (100 mM) for
7 days in (B). In (C), effects of knockdown of Ca-P60A are shown. Scale bars, 75 mm.
(D) Effect of thapsigargin on the growth of xenografted MOLT4 tumors. Error bars indicate mean ± SD of six replicates for the thapsigargin-treated and nine
replicates for the vehicle-treated mice. Statistical significance (**p < 0.01; ***p < 0.001) was determined by two-way ANOVA using Bonferroni’s correction for
multiple comparison testing.
(E) Effect of thapsigargin treatment on ICN1 levels in xenografted MOLT4 tumors was measured by western blotting, and statistical significance was determined
by Student’s t test (*p < 0.05). Error bars represent the mean ± SD of six replicates for each group.
(F and G) Effect of thapsigargin on the growth of DND41 cells transduced with MigR1 (F) or MigR1-ICN1 (G) xenografted in NSGmice. Error bars indicate mean ±
SD of replicates for each cohort. Statistical significance was determined by Student’s t test as indicated.
See also Figure S3.
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Figure 7. Notch1 Ca2+ Binding Modules Are
Required for the Anti-Notch1 Activity of
Thapsigargin
(A) Effect of SERCA coexpression on the activity of
DEGFDLNR in a Notch reporter assay. Normalized
firefly luciferase activity was expressed as fold
induction relative to the empty plasmid. Error bars
denote the mean ± SD of 10 replicates. Statistical
significance relative to pcDNA3 (***p < 0.001) and
to pcDNA3-DEGFDLNR (###p < 0.001) was deter-
mined by one-way ANOVA using Bonferroni’s
correction for multiple comparison testing.
(B and C) Effects of thapsigargin or Cpd E on the
activity of DEGFDLNR (B) and ICN1 (C) in a Notch
reporter assay. Assay conditions and interpreta-
tions were as in (A). Errors bars denote mean ± SD
of four replicates. Statistical significance (***p <
0.001) was determined by one-way ANOVA using
Bonferroni’s correction for multiple comparison
testing.
(D and E) The ICN1 protein level in SUPT1 cells
treated for 24 hr as indicated was determined
using immunoblots stained with anti-ICN1 anti-
body.
(F) Ligand-mediated activation of Notch activity
was determined using U2OS cells stably (Notch1
and Notch2) or transiently (L1601PDP) expressing
Notch-Gal4 fusion receptors and treated as indi-
cated. Normalized Gal4 firefly luciferase activity
was expressed relative to vehicle treated control.
Error bars denote mean ± SD of four replicates.
Statistical significance (**p < 0.01; ***p < 0.001)
was determined by Student’s t test.
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Sensitivity
The aforementioned results suggest that thapsigargin inhibits
signaling through wild-type and mutated Notch receptors but
may have stronger effect for mutated Notch1. Prior work has
shown that many activating HD mutations found in T-ALL result
in destabilization of the Notch negative regulatory region and
have deleterious effects on Notch1 folding and maturation
(Malecki et al., 2006). Because the Lin12/Notch repeats (LNRs)
of the Notch negative regulatory region rely on calcium for
folding and function (Aster et al., 1999), mutated Notch1 might
be more sensitive to reduced calcium availability than wild-
type Notch1, providing a therapeutic window for SERCA
inhibitors.
One simple prediction of the aforementioned model is that
constitutively active forms of Notch1 lacking Ca2+ binding
modules should be insensitive to SERCA inhibitors. To test this
prediction, we performed Notch1 reporter assays in U2OS cells
transfected with a plasmid encoding DEGFDLNR, a membrane-
tethered form of Notch1 lacking the extracellular epidermal
growth factor (EGF) repeats and LNRs, or ICN1. As anticipated,
coexpression of SERCA did not enhance reporter gene activa-
tion by DEGFDLNR (Figure 7A), nor was reporter gene activation
by DEGFDLNR (Figure 7B) or ICN1 (Figure 7C) affected by thap-Cancer Cell 23, 390–40sigargin. In contrast, DEGFDLNR was
highly sensitive to GSI (Figure 7B). Taken
together, these results indicate that, atlow nanomolar concentrations, thapsigargin inhibits Notch1
through a mechanism that requires the Ca2+-binding modules
of the Notch1 extracellular domain.
To determine if the Notch1 extracellular domain is important
for the ability of thapsigargin to inhibit leukemia cell growth, we
studied the human T-ALL cell line SUPT1, which has two copies
of a t(7;9)(q34,q34) fusing the 30 end of NOTCH1 with enhancer/
promoter elements of the T cell receptor b locus (TCRB) and has
no normal NOTCH1 allele (Ellisen et al., 1991). The rearranged
NOTCH1 alleles in SUPT1 cells drive the expression of a series
of truncated mRNAs encoding N-terminally deleted polypep-
tides lacking the Notch1 extracellular domain, some of which
are inserted into membranes and require g-secretase cleavage
for activation (Das et al., 2004). As anticipated, thapsigargin
had no effect on ICN1 levels in SUPT1 cells (Figure 7D), whereas
Cpd E eliminates the generation of ICN1 (Figure 7E). In line with
this idea that protein structure affects drug response, thapsigar-
gin failed to inhibit wild-type Notch1 or Notch2 at concentrations
that impaired signaling of Notch1-bearing leukemogenic HD
mutations (Figure 7F).
To further test the effect of thapsigargin on wild-type Notch1
maturation, we tested two Notch1 wild-type T-ALL and one
chronic myelogenous leukemia (CML) cell lines in which high
expression of Notch1 was previously reported (Palomero et al.,5, March 18, 2013 ª2013 Elsevier Inc. 399
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Figure 8. NOTCH1 Mutational Status Influ-
ences the Sensitivity to Thapsigargin
(A and B) Effect of thapsigargin treatment (6 hr) on
processing of HD mutant (A) or wild-type (B)
Notch1. Notch1 was detected with an antibody
against the C terminus of Notch1 that recognizes
the furin-processed Notch1 transmembrane
subunit (TM).
(C) Effect of thapsigargin treatment (24 hr) on
Notch1 cell surface staining, as assessed by flow
cytometry.
(D) The relative growth of thapsigargin-treated
T-ALL cell lines with wild-type (LOUCY, MOLT16,
and SUPT13) or rearranged alleles (SUPT1) of
NOTCH1 versus those with HD mutations (ALL/
SIL, DND41, KOPTK1, MOLT4, and PF382). The
line in the box plots represents the median. The
upper edge (hinge) of the box indicates the 75th
percentile of the data set, and the lower hinge
indicates the 25th percentile. The ends of the
vertical line indicate the minimum and the
maximum data values. Statistical significance was
determined by Student’s t test (*p < 0.05).
(E) Effect of thapsigargin treatment on cell cycle
progression in Notch1 wild-type cell lines, as as-
sessed by measurement of DNA content on the
viable fraction of cells.
(F) Effect of thapsigargin treatment (1 nM) on
apoptosis induction as assessed by the lumini-
nescence Caspase 3/7 assay. Errors bars denote
mean ± SD of four replicates. Statistical signifi-
cance (***p < 0.001) was determined by one-way
ANOVA using Bonferroni’s correction for multiple
comparison testing.
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to be less affected by thapsigargin treatment (Figures 8A–8C).
The effects of thapsigargin on cell viability were then determined
in a larger panel of human T-ALL cell lines of known NOTCH1
mutational status (Weng et al., 2004). Cell lines carryingNOTCH1
alleles with HD domain mutations were more sensitive to thapsi-
gargin than cells with wild-type NOTCH1 alleles or lacking the
Notch1 extracellular domain (Figures 8D–8F).
In summary, these data suggest that Notch1 receptors bearing
leukemogenic HD domain mutations are more sensitive to
SERCA inhibitors, such as thapsigargin, than normal receptors.
DISCUSSION
Integrating Cell-Based Screens for Small Molecule and
Protein Target Discovery
While there is a strong rationale for target-based therapies
for cancer, with the exception of the nuclear hormone recep-400 Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc.tors, transcription factors have largely
been refractory to conventional small-
molecule screening approaches due
to the challenges in developing high-
throughput, robust screening assays.
By definition, any therapeutic agent
that modulates a transcription factor
must alter the expression of its targetgenes. While there have been significant advances in our
ability to assess global gene expression changes, almost all
existing approaches cannot yet be applied to large-scale
screening efforts due to cost and throughput limitations.
Recognizing these shortcomings, we developed an approach
that allows measurement of the expression of hundreds of
endogenous genes in 384-well format and applied it to identify
antagonists of leukemogenic increases in Notch signaling in
T-ALL.
A limitation of both phenotypic and expression-based
screening, however, is that identification of the relevant target
of lead compounds can be difficult. The development of alterna-
tive genomic and chemical proteomic approaches for identifying
protein targets holds the promise of accelerating the elucidation
of underlying mechanism. Integrating results of a cDNA screen
with GE-HTS data allowed us to identify SERCAs as Notch1
modulators and potential therapeutic targets in Notch1-associ-
ated leukemias.
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Inhibition
We show here that SERCA inhibitors such as thapsigargin cause
a Notch1 maturation defect marked by the accumulation of
unprocessed Notch1 in the ER/Golgi compartment. The result-
ing effects on Notch1 signaling and leukemia cell growth depend
on the nature of the NOTCH1 mutations. The most common
activating NOTCH1 mutations in human T-ALL, the so-called
class INOTCH1mutations, consist of point substitutions or small
in-frame deletions or insertions in the extracellular heterodimeri-
zation domain, which disrupt heterodimerization domain struc-
ture and permit ligand-independent ADAM-type metallopro-
tease cleavages (Gordon et al., 2009; Malecki et al., 2006).
Folding and maturation of Notch1 are partially impaired by these
mutations (Malecki et al., 2006), and it appears that Notch1
receptors bearing suchmutations aremore sensitive to the inhib-
itory effects of thapsigargin than wild-type Notch1 receptors.
Another possible contributing factor to the greater sensitivity to
thapsigargin in cells with mutated Notch1 receptors is that the
presence of these mutated polypeptides may itself engender
ER stress and thus render these cells more susceptible to the
ER stress induced by thapsigargin. Indeed, this may account
for the inability to rescue fully the effects of thapsigargin with
ICN1 in some of our experiments. Taken together, these data
suggest the potential for a therapeutic window for thapsigargin
in T-ALLs bearing this type of mutation.
Other types of activating NOTCH1 mutations also exist.
Rarely, juxtamembrane in-frame tandem duplications create
new ‘‘deprotected’’ ADAM-metalloprotease cleavage sites
(class II mutations) (Malecki et al., 2006), or translocations create
NOTCH1 alleles encoding polypeptides that lack the Notch1
extracellular domain (Ellisen et al., 1991; Palomero et al.,
2006a). As anticipated, we observed that a T-ALL cell line with
two translocated NOTCH1 alleles is relatively resistant to thapsi-
gargin. Our proposed mechanism of action also predicts that
murine T-ALLs, which often have Notch1 deletions that remove
the Notch1 ectodomain coding sequence (Ashworth et al.,
2010), as well as uncommon human breast cancers with
NOTCH1 rearrangements (Robinson et al., 2011), will be more
resistant to thapsigargin and other SERCA inhibitors. It will be
of importance to determine if CLLs, which have recently been re-
ported to have frequent Notch1 PEST domain deletions (Di Ianni
et al., 2009; Puente et al., 2011) but lack heterodimerization
domain mutations, are sensitive to SERCA inhibitors.
Connecting NOTCH1 and SERCA Mutations in Human
Disease
Germline mutations in ATP2A1 are reported in the congenital
disorder Brody syndrome, characterized by impaired muscle
relaxation and myopathy (Odermatt et al., 1996). ATP2A2 muta-
tions are reported in Darier’s disease (Sakuntabhai et al., 1999),
an autosomal dominant skin disorder characterized by loss of
adhesion between keratinocytes, scaling due to hyperkeratosis,
and thickening of the epidermis due to keratinocyte hyperpro-
liferation. Skin cancers have been reported in patients with
Darier’s disease (Robertson and Sauder, 2012). Moreover, in
agedAtp2a2+/mice, tumors develop from the keratinized squa-
mous epithelia (Liu et al., 2001) while the wild-type Atp2a2 allele
is retained and expressed, supporting a role for SERCA2haploinsufficiency in tumor development (Prasad et al., 2005).
In addition, thapsigargin acts as a tumor promoter in a skin carci-
nogenesis mouse model (Hakii et al., 1986).
There is also mounting evidence that Notch signaling
suppresses the transformation of squamous epithelial cells.
Genetically engineered mice with decrements in Notch signaling
in the skin have a high incidence of skin cancers (Nicolas et al.,
2003; Proweller et al., 2006). Recent human clinical trial data
revealed that semagacestat, a GSI, is associated with an
increased risk of skin cancer (discussed in Crump et al., 2011),
possibly due to inhibition of Notch in the skin by chronic GSI
administration. Furthermore, Notch pathway loss-of-function
mutations have been reported in squamous cell carcinomas of
the head and neck (Agrawal et al., 2011; Stransky et al., 2011)
and of the skin and lung (Wang et al., 2011). Of note, at least
one NOTCH1 point substitution in human cutaneous squamous
cell carcinoma impairs Ca2+ binding and folding of EGF repeat 12
(Hambleton et al., 2004; Wang et al., 2011) and a second
(R1549Q) impacts folding of the LNRs (Wang et al., 2011), thus
recapitulating the proposed pharmacologic effect of thapsigar-
gin. Additional murine studies indicate that Notch signaling
may have a tumor suppressive function in other cell lineages
as well, including myeloid progenitors (Klinakis et al., 2011)
and endothelial cells (Liu et al., 2011; Yan et al., 2010). It is
intriguing that several recent studies report SERCA mutations
in head and neck squamous cell carcinoma (Korosec et al.,
2008; Stransky et al., 2011), in acute myeloid leukemia (Yan
et al., 2011), and in other malignancies (Korosec et al., 2009),
implicating loss-of-function mutations of SERCA as an addi-
tional possible mechanism for Notch inactivation in these
diseases. Indeed, while NOTCH1 mutations enhance sensitivity
to SERCA inhibitors, providing a potential therapeutic window
for application of this compound class, wild-type Notch1 is
also sensitive to SERCA inhibition but at higher concentrations
of the compound. One hypothesis to explain a Notch1 and
SERCA functional dependency is by a physical interaction. It
has been previously shown that presenilin and SERCA2b coloc-
alize in the ER (Green et al., 2008). Since presenilin immunopre-
cipitation is also reported to preferentially recover the full-length
Notch1 precursor prior to Notch1 cleavage in the Golgi (Ray
et al., 1999), it is possible that Notch1, SERCA, and presenilin
are part of a macromolecular complex.
Toward Translating SERCA Inhibitors to the Clinic
Our studies and other recent work bring to light a challenge in
targeting Notch1 in cancer: its pleiotropic roles. NOTCH1 is an
oncogene in some human cancers, such as T-ALL and CLL,
whereas it is a tumor suppressor in others, most notably, squa-
mous cell carcinomas. Several strategies have been explored to
inhibit Notch1 including the use of GSIs, Notch1-directed anti-
bodies, and direct inhibition of the Notch complex with a hydro-
carbon stapling approach (reviewed in Roti and Stegmaier,
2011). Each of these, however, is anticipated to also inhibit
wild-type Notch1. One strategy to mitigate potential cancer-
promoting effects in nondiseased cells is intermittent dosing of
Notch inhibitors. A second approach is the selective targeting
of the oncogenic protein. Our results suggest that common het-
erodimerization domain mutations in Notch1 render the protein
more susceptible to the thapsigargin-inducedmaturation defect,Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc. 401
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wild-type Notch1 (we observed an antileukemia effect with no
measureable gut toxicity). The selective targeting of BRAF
kinase bearing an activating V600E mutation by vemurafenib in
melanoma is an example of successful application of this
strategy (Bollag et al., 2010), although acquired resistance with
RAS pathway lesions is common (Nazarian et al., 2010; Su
et al., 2012). Similarly, reactivation of Notch1 signaling, for
example, by altered EGF/LNR repeats, may pose a resistance
mechanism in SERCA-targeted therapy in T-ALL.
Given the pervasive role of calcium signaling in normal
physiology, it is unlikely that pan-SERCA inhibitors such as
thapsigargin will have an immediate clinical application unless
additional development is pursued. One strategy might be the
development of isoform-specific small-molecule inhibitors of
SERCA. A second is to derivatize thapsigargin for specific
delivery to T-ALL cells. This tactic has already been used for
a derivative of thapsigargin that is designed to treat prostate
cancer, which is currently in clinical trials (NCT01056029 and
NCT01734681) (Denmeade et al., 2003). Successful ‘‘targeted’’
delivery of SERCA inhibitors to T-ALL cells would further improve
the therapeutic window with this class of drugs and enhance the
likelihood of clinical translation.
In summary, this study demonstrates the power of an
integrative screening strategy to identify alternative ways to
target aberrant transcription factors, identify the modulation of
SERCA as a tractable approach for inhibiting Notch1 in Notch-
driven cancers, and implicate SERCA mutation as another
potential pathogenic mechanism for Notch downregulation in
human cancers in which the Notch pathway has a tumor
suppressive role.
EXPERIMENTAL PROCEDURES
Full experimental details are in the Supplemental Experimental Procedures.
Cell Culture, Compounds, and Antibodies
Cells were cultured in RPMI 1640 (Cellgro) with 10% fetal bovine serum
(Sigma-Aldrich) and 1% penicillin-streptomycin. Cpd E, thapsigargin, and
cyclopiazonic acid were obtained from ENZO Life Sciences; and bepridil
hydrochloride, ionomycin, salinomycin, methotrexate, dexamethasone,
vincristine and DAPT were obtained from Sigma-Aldrich. We obtained western
blot antibodies against Notch1 from Cell Signaling and Santa Cruz Biotech-
nology, Actin from Thermo Scientific, Vinculin from AbCAM, and GAPDH
from Santa Cruz Biotechnology. Antibodies for immunofluorescence
include Notch1 [A6] and Giantin (AbCAM). Cell surface Notch1 was evaluated
by staining nonpermeabilized cells with monoclonal antihuman Notch1
antibody (R&D).
Notch1 Off Signature Detection
Marker and control genes for the Notch1 on versus off signature were chosen
using publicly available Affymetrix microarray expression profiling data sets
(GEO ID GSE5716) (Palomero et al., 2006b). Probes are shown in Supple-
mental Experimental Procedures. The signature was adapted to GE-HTS as
described elsewhere (Peck et al., 2006). Signature performancewas evaluated
by calculating the summed score and weighted summed score (Hahn et al.,
2008).
Small-Molecule Library Screening
DND41 cells were incubated with compounds at approximately 20 mM in
dimethyl sulfoxide (DMSO) for 72 hr. We screened 3,801 compounds in tripli-
cate, including the BSPBio collection (Prestwick, Biomol, and Spectrum
libraries) and the HSCI1 collection (Broad Institute). The GE-HTS assay was402 Cancer Cell 23, 390–405, March 18, 2013 ª2013 Elsevier Inc.performed as described elsewhere (Peck et al., 2006; Stegmaier et al.,
2004). Compounds that induce the Notch1 off signature were identified using
five discrete analytic metrics: summed score, weighted summed score,
K-nearest neighbor analysis, naive Bayes classification, and support vector
machine as described (Hahn et al., 2009).
cDNA Library Screen and Validation
The cDNA screening strategy involved the use of three key components: (1)
a pcDNA3 plasmid encoding a modestly strong NOTCH1 gain-of-function
mutant, L1601PDP, driven from a CMV promoter; (2) a Notch firefly luciferase
reporter; and (3) a preplated cDNA library cloned into the Sport6 plasmid.
Luminescence was measured 48 hr postplating.
Viral Transduction
Sequences targeted by each shRNA are listed in Supplemental Experimental
Procedures. Viral supernatant production and MigR1 retroviral infections were
performed as described (Aster et al., 2000).
Cell Growth, Apoptosis, and DNA Content Assays
Cell growth was assessed using the Promega Cell-Titer Glo ATP-based assay
(Promega), apoptosis using a Caspase-Glo 3/7 assay (Promega) or Annexin V
and propidium iodide (PI) staining by flow cytometry (eBioscience), and cellular
DNA content by staining with PI. Values for IC10, IC25, and IC50 (the concentra-
tion of an inhibitor where the response is reduced by 10%, 25%, and 50%,
respectively) were calculated using Prism 5 Software (Version 5.03).
Reporter Gene Assays
Expression plasmids for L1601PDP (Weng et al., 2004), L1601PDP-GAL4
(Malecki et al., 2006), DEGFDLNR (Chiang et al., 2008), and ICN1 (Aster
et al., 2000) have been described. Cotransfection of U2OS cells with expres-
sion plasmids, a Notch firefly luciferase reporter gene, and an internal Renilla
luciferase control gene, was performed as described elsewhere (Aster et al.,
2000). A second approach used a Notch1-Gal4 receptor ligand stimulation
assay (Malecki et al., 2006).
RT-PCR
Primers and probes for real-time (RT)-PCR were obtained from Applied
Biosystems. The data were analyzed using the DDCT method and plotted as
percentage of transcript compared to vehicle.
Drosophila Experiments
To generate RAF(gof) tumors in the adult Drosophila midgut, we created
a stock containing the UAS-RAF(gof) transgene on the X chromosome (Brand
and Perrimon, 1994) and the esg-Gal4, UAS-GFP, Tubulin, Gal80(ts) trans-
genes on the second chromosome (Micchelli and Perrimon, 2006). Drugs
were prepared in DMSO, mixed with fly food 1:100, and fed to flies for
7 days. Flies were given freshly prepared drug every 2–3 days. Drug effects
were evaluated by immunofluorescence microscopy.
T-ALL Xenograft Studies
MOLT4 xenografts were established by injecting 1.7 3 106 cells subcuta-
neously into 6-week-old female severe combined immunodeficiency (SCID)-
beige mice (Charles River Laboratories). Tumor volume was determined by
caliper measurements using this formula: volume = 0.5 3 length 3 weight
squared. When tumors reached a mean volume of 75 mm3, mice were divided
into two groups: 0.4 mg/kg thapsigargin or vehicle by intraperitoneal injection
daily. Three mice that died prematurely due to drug toxicity were excluded
from the study, leaving six evaluable mice in the thapsigargin-treated arm
and nine in the vehicle arm. DND41 MigR1 and DND41 MigR1-ICN1 xeno-
grafts were established by injecting 10 3 106 cells subcutaneously into
NSG mice (n = 20 per line). When tumor volume reached over 50 mm3, mice
were divided into two groups: 0.35 mg/kg thapsigargin or 10 ml/kg vehicle
by intraperitoneal injection daily. Mice that were not ready at start of treatment
were subsequently added to treatment groups when their tumors reached
appropriate sizes. Mice were treated daily through the course of the study,
and tumors were measured every 3 days. Five thapsigargin-treated mice
were found dead during the course of the study with no prior weight loss or
clinical signs of illness. All animal studies were performed under a protocol
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